These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 23489175)
21. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Shin DH; Feldman RM; Sheu WP; Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375 [TBL] [Abstract][Full Text] [Related]
23. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Gandolfi SA; Cimino L Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831 [TBL] [Abstract][Full Text] [Related]
24. Effects of topical administration of 0.005% latanoprost solution on eyes of clinically normal horses. Willis AM; Diehl KA; Hoshaw-Woodard S; Kobayashi I; Vitucci MP; Schmall LM Am J Vet Res; 2001 Dec; 62(12):1945-51. PubMed ID: 11763186 [TBL] [Abstract][Full Text] [Related]
25. 24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Konstas AG; Lake S; Economou AI; Kaltsos K; Jenkins JN; Stewart WC Arch Ophthalmol; 2006 Nov; 124(11):1553-7. PubMed ID: 17102001 [TBL] [Abstract][Full Text] [Related]
26. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study. Raber S; Courtney R; Maeda-Chubachi T; Simons BD; Freedman SF; Wirostko B; Ophthalmology; 2011 Oct; 118(10):2022-7. PubMed ID: 21788077 [TBL] [Abstract][Full Text] [Related]
27. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371 [TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma. Gupta SK; Agarwal R; Galpalli ND; Srivastava S; Agrawal SS; Saxena R Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):665-71. PubMed ID: 18200329 [TBL] [Abstract][Full Text] [Related]
29. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD; Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273 [TBL] [Abstract][Full Text] [Related]
30. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension. Friström B; Uusitalo H Acta Ophthalmol; 2010 Feb; 88(1):37-43. PubMed ID: 19900212 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Liu JH; Kripke DF; Weinreb RN Am J Ophthalmol; 2004 Sep; 138(3):389-95. PubMed ID: 15364220 [TBL] [Abstract][Full Text] [Related]
33. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918 [TBL] [Abstract][Full Text] [Related]
34. Effects of an unfixed combination of latanoprost and pilocarpine on the intraocular pressure and pupil size of normal dogs. Sarchahi AA; Abbasi N; Gholipour MA Vet Ophthalmol; 2012 Mar; 15 Suppl 1():64-70. PubMed ID: 22050700 [TBL] [Abstract][Full Text] [Related]
36. The combination latanoprost-timolol versus twice daily 0.50% timolol administration either associated or not with latanoprost: efficacy and tolerability in the primary open-angle glaucoma. Pacella E; Pacella F; Cavallotti C; Librando A; Feher J; Pecori-Giraldi J Eur Rev Med Pharmacol Sci; 2010 May; 14(5):477-80. PubMed ID: 20556928 [TBL] [Abstract][Full Text] [Related]
37. Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects. Altuna JC; Greenfield DS; Wand M; Liebmann JM; Taglia DP; Kaufman PL; Cioffi GA; Lee DA; Robin AL; Crichton A; Costa VP; Ritch R J Glaucoma; 1999 Jun; 8(3):199-203. PubMed ID: 10376261 [TBL] [Abstract][Full Text] [Related]
38. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye. Natarajan JV; Chattopadhyay S; Ang M; Darwitan A; Foo S; Zhen M; Koo M; Wong TT; Venkatraman SS PLoS One; 2011; 6(9):e24513. PubMed ID: 21931735 [TBL] [Abstract][Full Text] [Related]
39. A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect. Kobayashi H; Kobayashi K J Glaucoma; 2011 Jan; 20(1):3-6. PubMed ID: 20520573 [TBL] [Abstract][Full Text] [Related]
40. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy. Konstas AG; Mikropoulos D; Dimopoulos AT; Moumtzis G; Nelson LA; Stewart WC Br J Ophthalmol; 2008 Nov; 92(11):1498-502. PubMed ID: 18703549 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]